Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker

被引：14

作者：

Da Silva, F. ^{[1
,2
]}

Thomas-Schoemann, A. ^{[3
,4
,5
]}

Huillard, O. ^{[1
,2
]}

Goldwasser, F. ^{[1
,2
]}

Blanchet, B. ^{[3
,4
]}

机构：

[1] Cochin Hosp, AP HP, Dept Med Oncol, Paris, France

[2] Paris Descartes Univ, CARPEM, Paris, France

[3] Cochin Hosp, AP HP, Dept Pharmacokinet & Pharmacochem, Paris, France

[4] Paris Descartes Univ, Paris, France

[5] Univ Paris 05, PRES Sorbonne Paris Cite, Fac Pharm, CNRS,UMR8638, Paris, France

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷 / 08期

关键词：

D O I：

10.1093/annonc/mdw182

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In conclusion, our letter provides specific recommendations to oncologists and clinical pharmacists for the use of therapeutic drug monitoring in the management of potential pharmacokinetic interactions with calcium channel blocker during treatment with sunitinib in daily clinical practice.

引用

页码：1651 / 1652

页数：2